top of page
  • Recruiting

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Updated: Oct 4, 2022

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

SELIBORDARA

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma


Phase 2, single-arm, open, non-randomized, multicenter study of the SINE™ compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab.


Sponsor

 

ClinicalTrials.gov Identifier: NCT03589222

Official Title: An Open-label, Multicenter, Phase 2 Trial of Selinexor (KPT-330), Bortezomib and Low-dose Dexamethasone Plus Daratumumab (SELIBORDARA) for the Treatment of Patients With Refractory or Relapsed and Refractory Multiple Myeloma

First Posted : July 17, 2018

Click here for ClinicalTrials.gov

 
 

Drug: Selinexor

Drug: Daratumumab

Drug: Bortezomib

Drug: Dexamethasone

 

Locations

Europe

Spain

Comments


Posts Archive
bottom of page